Robert J. SCHNEIDER,Phillip A. GETER,Sofia BAKOGIANNI
申请号：
US16723573
公开号：
US20200197400A1
申请日:
2019.12.20
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Aspects of the technology are directed to a method of increasing sensitivity of estrogen receptor positive (ER+) breast cancer cells to treatment with an endocrine therapy. The method involves selecting ER+ breast cancer cells, and administering to the selected cells (i) one or more mammalian target of rapamycin (mTOR) inhibitors and (ii) one or moreMAP kinase-interacting serine/threonine-protein kinase 1 (MNK1) inhibitors in an effective amount to increase the sensitivity of the ER+ breast cancer cells to treatment with the endocrine therapy. Methods of treating a subject having ER+ breast cancer are also disclosed.
